c-Myc and its target foxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia

Hepatology

Volumn 48, Issue 4, 2008, Pages 1302-1311

  Blanco Bose, William E ^a   Murphy, Mark J ^a   Ehninger, Armin ^a   Offner, Sandra ^a   Dubey, Christelle ^a   Huang, Wendong ^b   Moore, David D ^c   Trumpp, Andreas ^a,d  

^a EPFL   (Switzerland)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 20; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLIN DEPENDENT KINASE 1; CYCLINE; MINICHROMOSOME MAINTENANCE PROTEIN; MUTANT PROTEIN; MYC PROTEIN; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; 1,4 BIS(2 (3,5 DICHLOROPYRIDYLOXY))BENZENE; 1,4-BIS(2-(3,5-DICHLOROPYRIDYLOXY))BENZENE; CELL RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, MOUSE; MYC PROTEIN, MOUSE; PYRIDINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE FUNCTION; GENE INDUCTION; HEPATOMEGALY; LIVER CELL; LIVER HYPERPLASIA; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG POTENTIATION; GENETICS; HYPERPLASIA; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; HEPATOCYTES; HYPERPLASIA; LIVER; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 54449087431     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22475     Document Type: Article

References (45)

1. Waxman DJ, Chen L, Hecht JE, Jounaidi Y. Cytochrome P450-based cancer gene therapy: Recent advances and future prospects. Drug Metab Rev 1999;31:503-522.
2. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000;407:920-923.
3. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23.
4. Qatanani M, Moore DD. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab 2005;6:329-339.
5. Diwan BA, Lubet RA, Ward JM, Hrabie JA, Rice JM. Tumor-promoting and hepatocarcinogenic effects of 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/ NCr rats initiated with N-nitrosodiethylamine. Carcinogenesis 1992;13:1893-1901.
6. Locker J, Tian J, Carver R, Concas D, Cossu C, Ledda-Columbano GM, et al. A common set of immediate-early response genes in liver regeneration and hyperplasia. HEPATOLOGY 2003;38:314-325.
7. Costa RH, Kalinichenko VV, Tan Y, Wang IC. The CAR nuclear receptor and hepatocyte proliferation. HEPATOLOGY 2005;42:1004-1008.
8. Huang W, Zhang J, Washington M, Liu J, Parant JM, Lozano G, et al. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol 2005;19:1646-1653.
9. Ledda-Columbano GM, Pibiri M, Concas D, Cossu C, Tripodi M, Columbano A. Loss of cyclin D1 does not inhibit the proliferative response of mouse liver to mitogenic stimuli. HEPATOLOGY 2002;36:1098-1105.
10. Ledda-Columbano GM, Pibiri M, Cossu C, Molotzu F, Locker J, Columbano A. Aging does not reduce the hepatocyte proliferative response of mice to the primary mitogen TCPOBOP. HEPATOLOGY 2004;40:981-988.
11. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005;7:126-136.
12. Baena E, Gandarillas A, Vallespinos M, Zanet J, Bachs O, Redondo C, et al. c-Myc regulates cell size and ploidy but is not essential for postnatal proliferation in liver. Proc Natl Acad Sci U S A 2005;102:7286-7291.
13. Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2004;2:e332.
14. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-1117.
15. Murphy MJ, Wilson A, Trumpp A. More than just proliferation: Myc function in stem cells. Trends Cell Biol 2005;15:128-137.
16. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-645.
17. Oskarsson T, Trumpp A. The Myc trilogy: Lord of RNA polymerases. Nat Cell Biol 2005;7:215-217.
18. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001;414:768-773.
19. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995;269:1427-1429.
20. Vincent SD, Robertson EJ. Targeted insertion of an IRES Cre into the Hnf4alpha locus: Cre-mediated recombination in the liver, kidney, and gut epithelium. Genesis 2004;39:206-211.
21. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004;18:2747-2763.
22. Psarros M, Heber S, Sick M, Thoppae G, Harshman K, Sick B. RACE: Remote Analysis Computation for gene Expression data. Nucleic Acids Res 2005;33.W638-W643.
23. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Riol 2003;4:P3.
24. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, et al. From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res 2006;34:D354-D357.
25. Fernandez LA, Winkler M, Grosschedl R, Matrix attachment region-dependent function of the immunoglobulin mu enhancer involves histone acetylation at a distance without changes in enhancer occupancy. Mol Cell Biol 2001;21:196-208.
26. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62:638-646.
27. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K Reid G, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004;279: 22250-22257.
28. Miao J, Fang S, Bae Y, Kemper JK. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. J Biol Chem 2006;281:14537-14546.
29. Blow JJ, Dutta A. Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol 2005;6:476-486.
30. Kneissl M, Putter V, Szalay AA, Grummt F. Interaction and assembly of murine pre-replicative complex proteins in yeast and mouse cells. J Mol Biol 2003;327:111-128.
31. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-134.
32. van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005;24:2844-2859.
33. Nasmyth K. How do so few control so many? Cell 2005;120:739-746.
34. Vanoosthuyse V, Hardwick KG. Bub1 and the multilayered inhibition of Cdc20-APC/C in mitosis. Trends Cell Biol 2005;15:231-233.
35. Wang X, Kiyokawa H, Dennewitz MB, Costa RH. The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci U S A 2002; 99:16881-16886.
36. Columbano A, Ledda-Columbano GM, Pibiri M, Cossu C, Menegazzi M, Moore DD, et al. Gadd45beta is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia. HEPATOLOGY 2005;42:1118-1126.
37. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003;17:1115-1129.
38. Oskarsson T, Essers MA, Dubois N, Offner S, Dubey C, Roger C, et al. Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev 2006;20:2024-2029.
39. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004;18:830-850.
40. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006;312:233-236.
41. Wierstra I, Alves J. FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2. FEBS J 2006;273:4645-4667.
42. Wierstra I, Alves J. FOXM1c and Sp1 transactivate the P1 and P2 promoters of human c-myc synergistically. Biochem Biophys Res Commun 2007; 352:61-68.
43. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, et al. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 2000; 60:5922-5928.
44. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 2003;100:8164-8169.
45. Brezillon N, Lambert-Blot M, Morosan S, Couton D, Mitchell C, Kremsdorf D, et al. Transplanted hepatocytes over-expressing FoxM1B efficiently repopulate chronically injured mouse liver independent of donor age. Mol Ther 2007;15:1710-1715.